Skip to main content
OpenTrials

Clinical trial condition

Prostatic Neoplasms

Explore clinical trials studying Prostatic Neoplasms. Study availability and eligibility vary by location and protocol.

36 public trials 14 recruiting studies
Refine in advanced search Browse all conditions

Prostatic Neoplasms trial results

Completed

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011

Conditions
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Androgen-Insensitive Prostatic Cance, +17 more
Locations
  • United Medical Group Miami, Florida, United States
  • Orlando Health Cancer Institute Orlando, Florida, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 61 locations
View Trial Details
Completed

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

NCT05293496

Conditions
Adenocarcinoma, Adnexal Diseases, Advanced Solid Tumor, +53 more
Locations
  • University of California, Los Angeles Los Angeles, California, United States
  • University of California, San Francisco San Francisco, California, United States
  • Florida Cancer Specialists and Research Institute Sarasota, Florida, United States
  • Winship Cancer Institute of Emory University Atlanta, Georgia, United States
View Trial Details
Completed

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

NCT04381832

Conditions
Androgen-Resistant Prostatic Neoplasms, Castration Resistant Prostatic Neoplasms, Genital Diseases, +11 more
Locations
  • The Oncology Institute of Hope & Innovation Cerritos, California, United States
  • The University of California, Los Angeles Encino, California, United States
  • The University of California, Irvine Medical Center Orange, California, United States
  • Florida Cancer Specialists South Sarasota, Florida, United States
View all 19 locations
View Trial Details
Completed

BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)

NCT02204072

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • NewYork-Presbyterian/Weill Cornell Medical Center New York, United States
  • Oregon Health and Sciences University Portland, Oregon, United States
  • Prince of Wales Hospital Hong Kong
View all 27 locations
View Trial Details
Completed

Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer

NCT02625857

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • San Francisco, California, United States
  • Baltimore, Maryland, United States
  • St Louis, Missouri, United States
  • Nashville, Tennessee, United States
View Trial Details
Completed

A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

NCT03016312

Conditions
Genital Diseases, Genital Diseases, Male, Genital Neoplasms, Male, +8 more
Locations
  • City of Hope Medical Grp Inc. Duarte, California, United States
  • University of California San Diego La Jolla, California, United States
  • Kaiser Permanente San Diego - Los Angeles Los Angeles, California, United States
  • UC Irvine Medical Center Orange, California, United States
View all 158 locations
View Trial Details

Related conditions